Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market
March 22, 2024 10:14 ET
|
Spherix Global Insights
Exton, Pennsylvania, March 22, 2024 (GLOBE NEWSWIRE) -- The end of 2023 introduced several new treatment options for patients suffering from ulcerative colitis (UC). Among them is Eli Lilly’s Omvoh...
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
February 26, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Data from SAD cohort expected to be shared during March corporate update; MAD cohorts to begin dosing in March.
Global Ulcerative Colitis Market Projected to Reach $9.48 Billion by 2028, Driven by Telemedicine and Innovative Therapies
February 20, 2024 04:45 ET
|
Research and Markets
Dublin, Feb. 20, 2024 (GLOBE NEWSWIRE) -- The "Ulcerative Colitis Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The ulcerative colitis market has grown...
Stoma/Ostomy Care Market to Reach US$ 4.2 Billion by 2028 Amid Rising Prevalence of IBD and Colorectal Cancer
February 16, 2024 07:01 ET
|
Research and Markets
Dublin, Feb. 16, 2024 (GLOBE NEWSWIRE) -- The "Stoma/Ostomy Care Market Report by Product (Ostomy Bags, Ostomy Accessories), End User (Home Care Settings, Hospitals & Specialty Clinics), Surgery...
Palisade Bio to Present at Digestive Disease Week (DDW) 2024
February 15, 2024 08:35 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious...
Crohn's Disease Treatment Market Set for Continued Growth, Reaching $16.32 Billion by 2028
January 29, 2024 18:59 ET
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Crohn's Disease Treatment Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The latest research publication on...
Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress
January 29, 2024 08:05 ET
|
Palisade Bio, Inc.
– Preclinical data demonstrated PALI-2108 to be safe and well tolerated – PALI-2108 is orally delivered and colon activated allowing for local activity with low systemic exposure – Company...
Global Inflammatory Bowel Disease Treatment Market Set to Soar with Predicted 5.84% CAGR by 2034
January 29, 2024 05:04 ET
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Global Inflammatory Bowel Disease Treatment Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. ...
Acute Pancreatitis Global Market Report 2024: Market to Surge to $7.41 Billion by 2028, Driven by Technological Advances and Growing Health Concerns - Long-term Forecast to 2033
January 25, 2024 09:14 ET
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Acute Pancreatitis Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The latest acute pancreatitis market...
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
January 24, 2024 02:30 ET
|
Abivax
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 PARIS,...